Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2026)

Cytek Biosciences has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $17.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 12.44% year-over-year to $17.7 million; the trailing twelve-month figure through Mar 2026 stood at $17.7 million (up 12.44% YoY), and the FY2025 full-year result was $18.3 million, up 13.92% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $17.7 million, down from $18.3 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $18.3 million in Q4 2025, with the low at $7.2 million in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $14.5 million across 5 years, with a median of $15.1 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 80.75% — and 2024, when it slipped 12.4%.
• Cytek Biosciences' Non-Current Deffered Revenue stood at $13.1 million in 2022, then increased by 15.3% to $15.1 million in 2023, then increased by 6.38% to $16.1 million in 2024, then gained by 13.92% to $18.3 million in 2025, then decreased by 3.64% to $17.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $17.7 million (Q1 2026), $18.3 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.